Praxis Precision Medicines, Inc. (PRAX)

Market Cap	725.47M
Revenue (ttm)	8.55M
Net Income (ttm)	-182.82M
Shares Out	20.16M
EPS (ttm)	-10.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	501,929
Open	35.79
Previous Close	35.34
Day's Range	35.53 - 37.09
52-Week Range	26.70 - 91.83
Beta	2.68
Analysts	Strong Buy
Price Target	123.33 (+242.77%)
Earnings Date	May 12, 2025

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PRAX
• Website: https://praxismedicines.com

Financial Performance

In 2024, PRAX's revenue was $8.55 million, an increase of 249.53% compared to the previous year's $2.45 million. Losses were -$182.82 million, 48.3% more than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is $123.33, which is an increase of 242.77% from the latest price.

Price Target

$123.33

(242.77% upside)

Analyst Consensus: Strong Buy